GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » Debt-to-EBITDA

Genelux (Genelux) Debt-to-EBITDA : -0.10 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Genelux Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genelux's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.65 Mil. Genelux's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.87 Mil. Genelux's annualized EBITDA for the quarter that ended in Dec. 2023 was $-26.24 Mil. Genelux's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.10.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genelux's Debt-to-EBITDA or its related term are showing as below:

GNLX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.22   Med: -2.01   Max: -0.1
Current: -0.1

During the past 4 years, the highest Debt-to-EBITDA Ratio of Genelux was -0.10. The lowest was -15.22. And the median was -2.01.

GNLX's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs GNLX: -0.10

Genelux Debt-to-EBITDA Historical Data

The historical data trend for Genelux's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genelux Debt-to-EBITDA Chart

Genelux Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-2.22 -1.80 -15.22 -0.10

Genelux Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.31 -0.10 -0.09 -0.09 -0.10

Competitive Comparison of Genelux's Debt-to-EBITDA

For the Biotechnology subindustry, Genelux's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genelux's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelux's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genelux's Debt-to-EBITDA falls into.



Genelux Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genelux's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.653 + 1.866) / -26.457
=-0.10

Genelux's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.653 + 1.866) / -26.24
=-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Genelux  (NAS:GNLX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genelux Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genelux's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genelux (Genelux) Business Description

Traded in Other Exchanges
N/A
Address
2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Executives
Tony Yu officer: VP, Clinical Trial Operations C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
John Thomas director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Aladar Szalay 10 percent owner C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Sean Ryder officer: General Counsel C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
John W Smither director C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Lourie S. Zak officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Thomas Zindrick director, officer: President and CEO C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE. 230, WESTLAKE VILLAGE CA 91361
Joseph Cappello officer: VP, Pharmaceutical Development C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Doug Samuelson officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Caroline Jewett officer: Head of Quality C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Ralph Smalling officer: Head of Regulatory C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Qian Zhang officer: Associate VP, Research C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Mary Mirabelli director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Paul Scigalla officer: Chief Medical Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361

Genelux (Genelux) Headlines